FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

BPC-157

Body Protection Compound-157 / Bepecin / PL 14736 / PL-10

Recovery & Repair

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is one of the most extensively researched peptides in preclinical models, with over 100 published studies demonstrating tissue-healing properties across tendons, ligaments, muscles, the gastrointestinal tract, and the nervous system. Despite robust animal data, no completed human clinical trials exist as of 2024.

作用機序

Pentadecapeptide derived from human gastric juice. Promotes angiogenesis via VEGF upregulation, accelerates tendon and ligament healing, modulates nitric oxide signaling, and protects endothelial cells. Demonstrates systemic healing properties across multiple tissue types.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 200-500mcg once or twice daily via subcutaneous injection near the injury site or systemically. Cycles of 4-12 weeks. Some protocols use oral administration at higher doses (500mcg-1mg).

研究ノート

Clinical Research Status

No completed human clinical trials. Extensive preclinical data across 100+ published studies in animal models. Currently being investigated by companies including Stabilitech Biopharma (oral formulation).

Key Published Findings

Demonstrated accelerated healing in rat models of Achilles tendon transection, medial collateral ligament rupture, and muscle crush injuries. Shown to promote angiogenesis (new blood vessel formation) through upregulation of VEGF and its receptor. Exhibits cytoprotective effects against NSAID-induced gastric damage in multiple studies.

Safety Profile

No significant toxicity reported in animal studies at standard research doses. No LD50 has been established (no lethal dose found). Remarkably wide safety margin in preclinical testing. Long-term human safety data does not exist.

Drug Interactions & Contraindications

May interact with dopaminergic and serotonergic systems. Shown to counteract the effects of dopamine agonists and antagonists in animal models. Potential interactions with medications affecting the nitric oxide system. Caution advised when combining with other growth-promoting compounds.

Comparison to Related Compounds

Often compared to and stacked with TB-500 (Thymosin Beta-4). BPC-157 tends to be more localized in its healing effects while TB-500 is more systemic. Unlike most peptides, BPC-157 is stable at gastric pH, enabling oral administration without significant degradation.

Community Observations

Widely used in the biohacking and athletic recovery community. Anecdotal reports consistently describe accelerated recovery from soft tissue injuries. Some users report improved gut function and reduced inflammation. Injection site reactions are the most commonly reported side effect.

半減期

~4 hours

再構成

Bacteriostatic water (BAC)

保存

乾燥粉末

Refrigerate 2-8C up to 24 months. Protect from light.

再溶解

Refrigerate 2-8C. Use within 14 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

Body Protection Compound-157BepecinPL 14736PL-10

よくある質問

BPC-157とは何ですか?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is one of the most extensively researched peptides in preclinical models, with over 100 published studies demonstrating tissue-healing properties across tendons, ligaments, muscles, the gastrointestinal tract, and the nervous system. Despite robust animal data, no completed human clinical trials exist as of 2024.

BPC-157はどのように作用しますか?

Pentadecapeptide derived from human gastric juice. Promotes angiogenesis via VEGF upregulation, accelerates tendon and ligament healing, modulates nitric oxide signaling, and protects endothelial cells. Demonstrates systemic healing properties across multiple tissue types.

BPC-157の米国での規制状況は?

Research chemical (not FDA-approved)

BPC-157の半減期は?

~4 hours

BPC-157の別名は?

Body Protection Compound-157, Bepecin, PL 14736, PL-10

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む